Last reviewed · How we verify
AJU-A51
AJU-A51 is a small molecule drug that targets the SGLT2 receptor.
AJU-A51 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | AJU-A51 |
|---|---|
| Sponsor | AJU Pharm Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, AJU-A51 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful for treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients (PHASE3)
- Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |